Pharmacologic Relapse Prevention for Alcoholic Smokers

Smoking Clinical Trial

Official title:

Pharmacologic Relapse Prevention for Alcoholic Smokers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00000457
• Other study ID #: 972-95
• Secondary ID: R01AA011219
• Status: Completed
• Phase: Phase 2
• First received: November 2, 1999
• Last updated: October 18, 2013
• Start date: June 1998
• Est. completion date: August 2007

Study information

• Verified date: October 2013
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.

Description:

The purpose of this trial was to recruit 292 recovering alcoholic smokers (abstinent from alcohol for a minimum of 1 year), who want to stop smoking and provide them with 100% nicotine replacement. The 100% nicotine replacement will be undertaken using a nicotine patch. By measuring their nicotine levels at study entry we can determine the patch dosing needed. The patch dosing will vary from 22 mg to 44 mg. Those who are able to achieve tobacco abstinence by week 8 will enter a relapse prevention phase for the remaining 44 weeks. In this phase, they will be randomized to active or placebo bupropion (300 mg/day). After 44 weeks of the relapse prevention trial (at week 52 of study participation), they will enter a post medication follow up for 6 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 195
• Est. completion date: August 2007
• Est. primary completion date: April 2002
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• History of alcohol dependence and at least one year of abstinence from alcohol intake.

• Has a history of smoking 20 or more cigarettes per day for the prior year.

• Can read and write English.

• Stated ability to fully participate in the study and keep all scheduled appointments.

• Has provided written informed consent.

• General good health.

Exclusion Criteria:

• Recent history (within three months) of a clinically significant myocardial infarction, unstable angina pectoris, serious cardiac arrhythmia or any other medical condition which the physician investigator deems incompatible with study participation.

• Current major depression. A past history of major depression will not be an exclusionary criteria.

• Current or previous use of bupropion (Wellbutrin).

• Active non- nicotine drug dependence.

• Past or current history of bipolar disorder, pain disorder or psychosis, schizophrenia, or other major psychiatric disorders.

• Current medically indicated use of psychiatric drugs.

• Females who are pregnant, lactating, or likely to become pregnant during the first year which includes the nicotine patch and bupropion (Wellbutrin) phase.

• History of severe skin allergies or evidence of severe chronic skin disorders.

• Current use of nicotine containing medication or tobacco products other than cigarettes.

• Current use (within 30 days of initiation of patch therapy) of the following medications for smoking cessation: clonidine, buspirone, or doxepin.

• A predisposition to seizures.

• A history of or current diagnosis of anorexia nervosa or bulimia.

• Medical disorder that would interfere with the absorption, metabolism, or excretion of bupropion (Wellbutrin).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Alcoholism
• Smoking

Intervention

Drug:
• bupropion (Wellbutrin)
1 pill in the am of 150 mg of Bupropion 1 pill (150 mg) in the AM and one in the PM for a total of 300 mg per day for subsequent 44 weeks.
• Placebo
placebo pill to match (look alike) the 150 mg pill of the bupropion given in the am for 3 days and then two pills (one in the morning and one at night) for the subsequent 44 mg.

Locations

Country	Name	City	State
United States	Mayo Clinic Rochester	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

References & Publications (2)

Hays JT, Hurt RD, Decker PA, Croghan IT, Offord KP, Patten CA. A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics. Nicotine Tob Res. 2009 Jul;11(7):859-67. doi: 10.1093/ntr/ntp077. Epub 20 — View Citation

Hurt RD, Patten CA, Offord KP, Croghan IT, Decker PA, Morris RA, Hays JT. Treating nondepressed smokers with alcohol dependence in sustained full remission: nicotine patch therapy tailored to baseline serum cotinine. J Stud Alcohol. 2005 Jul;66(4):506-16. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Will bupropion reduce relapse to smoking compared to placebo	Determine if long-term use of bupropion will reduce the rate of relapse to smoking compared to placebo in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy projected to achieve 100% replacement.	52 weeks and 76 weeks	No
Secondary	Does matching the dose of nicotine patches to nicotine levels help increase smoking abstinence	Determine the week 8 smoking cessation rate in recovering alcoholics provided a nicotine patch dose projected to achieve 100% replacement.	8 weeks	No